Clinical trials: Osteoporosis Postmenopausal
Osteoporosis in Post-menopausal Women, Osteoporosis
Intravenous Infusion of Human Mesenchymal Stem Cells (HMM910 ) in Postmenopausal Women With Osteoporosis at High Risk of Fracture
The primary objective of this study is to evaluate the safety and tolerability of human umbilical cord-derived mesenchymal stem cells for injection (HMM910 ) in postmenopausal women with osteoporosis who are at high risk of…
- Trial name
- NCT06949137
- Testing
- Human Umbilical Cord-derived Mesenchymal stem cell
- Where
- China
- Volunteers
- 9 people
- Sponsor
- HELP Therapeutics Co., Ltd.
Bone Loss
The Prevention Of Postmenopausal Osteoporosis With Lasofoxifene And Cytokine Evaluation
The objective of the study is to demonstrate the effects that lasofoxifene has on serum markers of bone metabolism.
- Trial name
- LACE (NCT00674453)
- Testing
- Lasofoxifene
- Where
- United Kingdom
- Volunteers
- 51 people
- Sponsor
- Ligand Pharmaceuticals
Osteoporosis
A Study to Assess the Safety and Efficacy of 3 Doses of ALX1-11 (50, 75, and 100µg) in the Treatment of Postmenopausal Osteoporosis
A double-blind, placebo-controlled, parallel-group study to assess the safety and efficacy of 3 doses of ALX1-11 (recombinant human parathyroid hormone [rhPTH(1-84)])(50, 75 and 100 µg) in the treatment of postmenopausal…
- Trial name
- NCT00172107
- Testing
- ALX1-11 50 mcg, ALX1-11 75mcg, ALX1-11
- Where
- 19 sites in United States, Canada
- Volunteers
- 217 people
- Sponsor
- Shire
Osteoporosis, Postmenopausal, Osteoporosis
Early Effects of Abaloparatide on Tissue-Based Indices of Bone Formation and Resorption
The objective of this study is to measure the early effects of abaloparatide on tissue-based bone formation using samples obtained by transiliac crest bone biopsy after quadruple fluorochrome labeling.
- Conditions
- Osteoporosis, Postmenopausal, Osteoporosis, Osteoporosis Vertebral, Osteoporosis Risk
- Trial name
- NCT03710889
- Testing
- Abaloparatide
- Where
- 4 sites in United States
- Volunteers
- 23 people
- Sponsor
- Radius Health, Inc.
Postmenopausal Osteoporosis
Efficacy and Safety of Actonel® After Denosumab Discontinuation in Postmenopausal Osteoporosis Women
To evaluate the effect of 1 year of risedronate treatment on the prevention of bone loss after denosumab discontinuation in denosumab-treated post-menopausal osteoporosis for a year
- Trial name
- NCT05630768
- Testing
- Risedronate Sodium 35 MG [Actonel], Calcium Vitamin D combination
- Where
- South Korea
- Volunteers
- 149 people
- Sponsor
- Dong-A ST Co., Ltd.
Postmenopausal Osteoporosis
Study to Evaluate AMG 162 in the Prevention of Postmenopausal Osteoporosis
This study will determine whether treatment with AMG 162 can prevent lumbar spine bone loss in both early and late postmenopausal women with osteopenia, and to further test the safety and tolerability of AMG 162 in this…
- Trial name
- NCT00091793
- Testing
- AMG 162
- Volunteers
- 332 people
- Sponsor
- Amgen
Post-Menopausal Osteoporosis
Intra-venous Zoledronic Acid Once Yearly
The study will assess the real life effectiveness of zoledronic acid in the management of patients with osteoporosis over 4 years of treatment.
- Trial name
- IVORY (NCT00984893)
- Testing
- zoledronic acid, Any oral bisphosphonates marketed in Canada
- Where
- 3 sites in Canada
- Volunteers
- 1,551 people
- Sponsor
- Novartis Pharmaceuticals
Osteoporosis
A Six-month Phase 2 Study of Oral hPTH(1-34) (EBP05) in Postmenopausal Women With Low Bone Mass
This is a double-blinded randomized study to determine the effects of treatment on biochemical markers of bone formation and bone resorption, and bone mineral density (BMD) for 6 months of treatment with EBP05 or placebo.
- Trial name
- NCT04003467
- Testing
- EBP05
- Where
- 4 sites in Israel
- Volunteers
- 161 people
- Sponsor
- Entera Bio Ltd.
Osteoporosis
Efficacy and Safety of AAE581 in Postmenopausal Women With Osteopenia/Osteoporosis.
AAE581 is a specific inhibitor of the cysteine protease cathepsin K. This trial is designed to provide detailed information about the effects( efficacy and safety) of AAE581 on Bone Mineral Density.
- Trial name
- NCT00170911
- Testing
- AAE581
- Volunteers
- 160 people
- Sponsor
- Novartis Pharmaceuticals
Postmenopausal Osteoporosis
Comparing of the Pharmacokinetic, Safety and Immunogenicity of HS-20090-2 Injection and Prolia® in Healthy Adults
A randomized, single-blind and parallel group study to compare the pharmacokinetic, safety and immunogenicity of HS-20090-2 60mg#1ml#and Prolia® in healthy adults.
- Trial name
- NCT04940845
- Testing
- HS-20090-2, Prolia
- Where
- China
- Volunteers
- 174 people, healthy volunteers welcome
- Sponsor
- Shanghai Hansoh Biomedical Co., Ltd
Postmenopausal Osteoporosis
A Safety and Efficacy Study to Evaluate Romosozumab (AMG 785) in South Korean Women With Osteoporosis
The primary objective is to evaluate the effect of treatment with romosozumab for 6 months compared with placebo on percent changes in bone mineral density (BMD) at the lumbar spine as assessed by dual-energy X-ray absorptiometry…
- Trial name
- NCT02791516
- Testing
- Romosozumab
- Where
- 10 sites in South Korea
- Volunteers
- 67 people
- Sponsor
- Amgen
Osteoporosis, Post-menopausal
Effects of Teriparatide or Zoledronic Acid Treatment on Bone in Postmenopausal Osteoporotic Women
The purpose of this study is to investigate how teriparatide or zoledronic acid affects the bone of postmenopausal osteoporotic women after 6 months of treatment as determined by a bone biopsy sample taken from the iliac crest…
- Trial name
- NCT00927186
- Testing
- Teriparatide, Zoledronic Acid
- Where
- 12 sites in United States, Canada
- Volunteers
- 69 people
- Sponsor
- Eli Lilly and Company
Postmenopausal Osteoporosis
The Effects of Denosumab on the Pharmacokinetics (PK) of Midazolam
This is a multi-center, open-label, drug-drug interaction study in postmenopausal women with osteoporosis.
- Trial name
- NCT01221727
- Testing
- Denosumab, Midazolam
- Volunteers
- 30 people
- Sponsor
- Amgen
Postmenopausal Osteoporosis
A Study of Once Monthly Bonviva (Ibandronate) in Prevention of Glucocorticoid-Induced Osteoporosis.
This 2 arm study will investigate the efficacy and safety of Bonviva (150mg po monthly) in the prevention of glucocorticoid-induced osteoporosis in post-menopausal women.
- Trial name
- NCT00545051
- Testing
- ibandronate
- Where
- 15 sites in Finland
- Volunteers
- 140 people
- Sponsor
- Hoffmann-La Roche
Osteoporosis Postmenopausal
Efficacy and Safety Study of Fosamax Plus D in Postmenopausal Women With Osteoporosis (0217A-263)
To demonstrate the efficacy/safety of Fosamax Plus D
- Trial name
- NCT00729651
- Testing
- alendronate sodium (+) cholecalciferol, Comparator: Alendronate sodium (Fosamax), Comparator: Calcium
- Volunteers
- 343 people
- Sponsor
- Organon and Co
Post Menopausal Osteoporosis
MOBILE Study - A Study of Bonviva (Ibandronate) Regimens in Women With Post-Menopausal Osteoporosis
This study will compare the efficacy and safety of different treatment regimens of oral Bonviva tablets in women with post-menopausal osteoporosis. Patients will also receive daily supplementation with vitamin D and calcium.
- Trial name
- NCT00048061
- Testing
- Ibandronate [Bonviva/Boniva], Calcium, Vitamin D
- Where
- 68 sites in United States, Australia and 17 more
- Volunteers
- 1,609 people
- Sponsor
- Hoffmann-La Roche
Osteoporosis, Vitamin D Deficiency
A Study of MK0217A and Dietary Supplement in Men and Postmenopausal Women With Osteoporosis (0217A-227)
The purpose of this study is to test the safety, tolerability, and effectiveness of an investigational drug and dietary supplement to reduce the risk of vitamin D insufficiency and deficiency during treatment of osteoporosis in…
- Trial name
- NCT00092079
- Testing
- MK0217A, alendronate sodium (+) cholecalciferol / Duration of Treatment: 24 weeks
- Volunteers
- 652 people
- Sponsor
- Merck Sharp & Dohme LLC
Osteoporosis, Postmenopausal
Generic Zoledronic Acid Versus Original Zoledronic Acid in Postmenopausal Osteoporotic Women
This study compares the efficacy and safety of generic zoledronic acid (Yigu®) and original zoledronic acid (Aclasta®) in the treatment of postmenopausal osteoporotic women in China.
- Trial name
- NCT03158246
- Testing
- Generic Zoledronic Acid, Original Zoledronic Acid, calcium
- Volunteers
- 466 people
- Sponsor
- Cttq
Postmenopausal Osteoporosis
A Study of Monthly Risedronate for Osteoporosis
The purpose of this trial is to study the efficacy of a single-dose monthly dosing regimen as compared to the standard daily dosing regimen of risedronate 5 mg daily.
- Trial name
- NCT00247273
- Testing
- risedronate
- Where
- 49 sites in United States, Argentina and 12 more
- Volunteers
- 1,294 people
- Sponsor
- Warner Chilcott
Postmenopausal Osteoporosis
A Study of Ibandronate (Boniva) to Evaluate Satisfaction in Women With Post-Menopausal Osteoporosis or Osteopenia
This study will investigate participant satisfaction (including compliance, preference, tolerability) with once-monthly Bonviva in women with post-menopausal osteoporosis or osteopenia transitioned from once-weekly alendronate or…
- Trial name
- NCT02604836
- Testing
- Ibandronate
- Where
- 142 sites in United States
- Volunteers
- 1,711 people
- Sponsor
- Hoffmann-La Roche